HBx Downregulates TFEB via the CUL4A/CUL4B-DDB1 Axis to Disrupt Lysosomal Function in Hepatocellular Carcinoma Cells.
Level 5 - mechanism / opinion, no new human data
In vitro bench mechanistic study with no human clinical data
PubMed 42505369 · doi:10.3390/cells15141259
What was done
Authors investigated the molecular mechanism through which the hepatitis B virus X protein (HBx) alters lysosomal biogenesis and autophagic degradation in hepatocellular carcinoma cells. Using wild-type HBx and DDB1-binding-deficient mutants (HBx R96E and HBx ΔDBD), they tested the role of transcription factor EB (TFEB) and the CUL4A/CUL4B-DDB1 E3 ubiquitin ligase complex in lysosomal acidification and autophagosome-lysosome fusion.
What was found
The abstract provides no numerical values, effect sizes, or statistical metrics. Qualitatively, HBx downregulated TFEB, leading to impaired lysosomal acidification and autophagosome-lysosome fusion via the CUL4A/CUL4B-DDB1 complex. Mutant HBx proteins defective in DDB1 binding failed to downregulate TFEB or alter lysosomal function.
Why it matters
The study outlines a specific molecular pathway by which HBx suppresses TFEB-mediated lysosomal function, identifying the CUL4A/CUL4B-DDB1-TFEB axis as a candidate mechanistic target in HBV-associated liver disease.
Limits
The abstract reports no quantitative data or specific cell line details. As an in vitro study, it lacks validation in animal models of chronic hepatitis B infection or clinical liver tissue samples.
Cited by
- supports TFEB is the master transcription factor that regulates lysosome biogenesis.